Abstract: Provided is an anesthetic composition for locally administrating an amide-type anesthetic into a subject in need thereof. The anesthetic composition has multilamellar vesicles with entrapped amide-type anesthetic prepared by hydrating a highly entrapped lipid structure comprising an amide-type anesthetic and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more feasible process for large-scale manufacture and for providing a high molar ratio of amide-type anesthetic to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.
Abstract: There is disclosed a salt of Formula III, a method for manufacturing thereof as well as uses thereof. (Formula III), wherein X is H or OH, Y is H or a cation selected from the group consisting of Li, Na and K, is a single bond or a double bond, and n is 0.5 or 1.
Type:
Grant
Filed:
May 20, 2020
Date of Patent:
April 15, 2025
Assignee:
IRL 790 AB
Inventors:
Inese Reine, Clas Sonesson, Ross Nicholas Waters, Joakim Mihkel Tedroff
Abstract: The present disclosure relates to birch bark extracts, methods of producing such extracts, stable pharmaceutical compositions containing such extracts and methods of using of such extracts. The birch bark extracts of the present disclosure contain triterpenes, which are known to improve wound healing.
Type:
Grant
Filed:
October 23, 2023
Date of Patent:
April 8, 2025
Assignee:
Amryt Pharmaceuticals Designated Activity Company
Inventors:
John Ashleigh Watson, Sebastian Jäger, Tobias Zahn
Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.
Type:
Grant
Filed:
December 7, 2021
Date of Patent:
April 8, 2025
Assignee:
Emory University
Inventors:
Raymond F. Schinazi, Keivan Zandi, Franck Amblard
Abstract: A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10); wherein the ratio of MCT-C8 to MCT-C10 is from 10:90 to 90:10 (mol/mol) and wherein the combined amount of MCT-C8 and MCT-C10 make up at least 50 mol % of the MCTs in the composition.
Abstract: In one aspect, the disclosure relates to compounds that are inhibitors of KRAS, and the disclosed compounds are allosteric inhibitors of KRAS which render them extremely useful for therapeutic intervention in a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, e.g., cancer. In various aspects, the disclosed compounds are substituted 7-(piperazin-1-yl)pyrazolo[1,5-a]pyrimidine analogs. In further aspects, the disclosed compounds can be used in methods of treating a cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Type:
Grant
Filed:
September 8, 2021
Date of Patent:
March 18, 2025
Inventors:
Alemayehu Gorfe Abebe, Michael J. McCarthy, Cynthia V. Pagba, Priyanka Prakash Srivastava
Abstract: The present invention derives from the unexpected finding that ADRA2a antagonists decrease fibrosis in non-alcoholic fatty liver disease (NAFLD). Thus, by antagonising ADRA2a, many of the unwanted consequences or symptoms of NAFLD, may be reduced, such as impaired cognitive activity and fibrosis progression. The present invention utilises these findings to identify and provide ADRA2a antagonists that may be used in the treatment of fibrosis in NAFLD.
Abstract: Methods and compositions that can be used to modulate the activity of furin in a subject are disclosed herein. In some embodiments, the methods include administering a pharmaceutical composition including a protease inhibitor. In some embodiments, the protease inhibitor inhibits furin activity by binding to the catalytic site, the allosteric site, or both.
Abstract: The present invention features a method of reducing tactile dysfunction or anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett Syndrome, or Fragile X syndrome by administering a GABAA agent having reduced blood brain barrier or by expressing a nucleic acid encoding an exogenous alpha or beta subunit of a GABAA receptor in dorsal root ganglion neurons in the subject using a vector.
Type:
Grant
Filed:
June 21, 2022
Date of Patent:
January 21, 2025
Assignee:
President and Fellows of Harvard College
Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
Type:
Grant
Filed:
July 10, 2023
Date of Patent:
January 21, 2025
Assignee:
PAION UK LTD.
Inventors:
Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
Abstract: Compounds and methods for modulating the activity of receptors are disclosed. Some of the compounds modulate the activity of glycine receptors. Certain embodiments of the compounds are useful for treatment of pain, treatment of opioid addiction, and/or reduction of side effects attributable to opioid use.
Type:
Grant
Filed:
September 8, 2022
Date of Patent:
January 14, 2025
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
Type:
Grant
Filed:
August 10, 2022
Date of Patent:
December 24, 2024
Assignee:
AMARIN PHARMACEUTICALS IRELAND LIMITED
Inventors:
Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
Type:
Grant
Filed:
May 23, 2019
Date of Patent:
December 24, 2024
Assignee:
VENATORX PHARMACEUTICALS, INC.
Inventors:
Christopher J. Burns, Denis Daigle, Guo-Hua Chu, Jodie Hamrick, Steven A. Boyd, Allison L Zulli, Eugen F. Mesaros, Stephen M. Condon, Robert E. Lee Trout, Cullen L. Myers, Zhenrong Xu
Abstract: A composition comprising: (i) a mixture containing a lipid-soluble vitamin dissolved in a lipid, and (ii) bran; wherein the mixture is absorbed into and/or adsorbed onto the bran and wherein the lipid does not originate from the bran. Also provided are processes for providing a stabilised vitamin composition.
Type:
Grant
Filed:
January 25, 2017
Date of Patent:
December 17, 2024
Assignee:
Societe des Produits Nestle S.A.
Inventors:
Cyril Moccand, Laurent Sagalowicz, Nicola Galaffu, Martin Michel, Edwin Alberto Habeych Narvaez
Abstract: The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.
Type:
Grant
Filed:
June 12, 2019
Date of Patent:
December 10, 2024
Assignee:
RYVU THERAPEUTICS S.A.
Inventors:
Monika Patrycja Dobrzanska, Magdalena Izabela Zawadzka, Adam Radzimierski, Grzegorz Witold Topolnicki, Grzegorz Wojciech Cwiertnia, Tushar Ravindra Mahajan, Charles-Henry Fabritius, Stefan Chmielewski, Karolina Maria Gluza, Jose Alvarez, Maciej Krzysztof Rogacki, Magdalena Mroczkowska
Abstract: The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.
Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.
Type:
Grant
Filed:
May 5, 2023
Date of Patent:
November 12, 2024
Assignee:
SLAYBACK PHARMA LLC
Inventors:
Sushant Omprakash Dube, Suprit Dilip Saoji, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai, Girish G. Kore